期刊文献+

沙利度胺维持治疗对小细胞肺癌患者无进展生存期的影响 被引量:6

下载PDF
导出
摘要 目的:应用沙利度胺进行小细胞肺癌的维持治疗,以延长小细胞肺癌患者无进展生存期(PFS)。方法:32例完成规定周期化疗的SCLC患者,随机分为治疗组和对照组各16例,治疗组应用沙利度胺100mg/d,连续口服,21天为1疗程,治疗至少2个疗程,对照组定期复查随访。结果:治疗组和对照组PFS分别为4.86个月和4.20个月,两组有明显差异(P=0.044)。结论:沙利度胺可延长SCLC患者的无进展生存期。
出处 《现代肿瘤医学》 CAS 2012年第2期320-322,共3页 Journal of Modern Oncology
  • 相关文献

参考文献11

  • 1Feld R,Evans WK,DeBoer G,et al.Combined modality induction therapy without maintenance chemotherapy for small cell carcinoma of the lung[J].J Clin Oncol,1984,2(4):294-304.
  • 2Jokman DM,Johnson BE.Small cell lung cancer[J].Lancet,2005,366:1385.
  • 3范云.进展期非小细胞肺癌维持治疗新进展.中国临床肿瘤学教育专辑(2008).北京:中国协和医科大学出版社,2008:67-71.
  • 4Ldie JH,Coldman AJ.A mathematical model for relating the drug sensitivity of tunlors to their spontaneous mutation rate[J].CancerTreat Rep,1979,63(1l-2):1727-1733.
  • 5马芳,黄学惠.沙利度胺的抗肿瘤作用及临床用途研究进展[J].现代肿瘤医学,2009,17(9):1799-1802. 被引量:16
  • 6PUJOL J L,BRETON J L,GERVAI S R,et al.Phase Ⅲ double-blind,placebo-contrololled study of thalidomide in extensive-disease small-cell lung cancer After response to chemotherapy:an intergroup study FNCLCC leo04-IFCT00-01[J].J Clin Oncol,2007,25(25):3945-3951.
  • 7LEE SM,WOLL P J,RUDD R,et al.Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer:a randomized,double-blind,placebo-controlled trial[J].J Nail Cancer Inst,2009,101(15):1049-1057.
  • 8王彩玲,王俊生.IP方案联合沙利度胺二线治疗晚期小细胞肺癌的临床观察[J].实用癌症杂志,2011,26(1):89-90. 被引量:28
  • 9何秋山,易铁男,罗斌,张小灵.NP方案联合与不联合沙利度胺治疗晚期非小细胞肺癌的临床随机对照研究[J].中国肺癌杂志,2008,11(2):264-267. 被引量:10
  • 10Tosi P,Zamagni E,Collini C,et al.Thalidomidealone or in combination with dexamethasone in patients with advanced.relapsed or refractory multiple myeloma and renal failure[J].Euro J Haemat,2004,73:98-108.

二级参考文献21

  • 1Ana Teresa Carvalho,Heitor Souza,Antonio Jose Carneiro,Morgana Castelo-Branco,Kalil Madi,Alberto Schanaider,Flavia Silva,Fernando Antonio Pereira Júnior,Márcia G Pereira,Cláudio Tortori,Ilana Dines,Jane Carvalho,Eduardo Rocha,Celeste Elia.Therapeutic and prophylactic thalidomide in TNBS-induced colitis: Synergistic effects on TNF-α, IL-12 and VEGF production[J].World Journal of Gastroenterology,2007,13(15):2166-2173. 被引量:6
  • 2Ayman Saad,Robert Beto.Cardiovascular safety and toxicity pro-file of new molecularly targeted antieaneer agents[J].American Society of Clinical Oneology,2008,428-433.
  • 3Strevel EL,Ing DJ,Siu LL Molecularly targeted oneology thera-peutics and prolongation of the QT interval[J].Clin Oncol,2007.3362-3371.
  • 4J - kman DM, Johnson BE. Small cell lung cancer[ J ]. Lancet,2005, 366 (9494) : 1385.
  • 5Vanhoefer U, Harstrick A, Achterrath W, et al. Irinotecan in the treat- merit of colorectal cancer:clinical overview(J). J Clin Oncol,2001,19 (5) :1501.
  • 6Hirose T,Horiehi N, Ohmofi T,et al. Phase Ⅱ study of irinoteean and earboplatin in patients with the refractory or relapsed small cell lung cancer [ J ]. Lung Cancer,2003,40 ( 3 ) :333.
  • 7Jagasia MH,Langer C J, Johnson DH, et al. Weekly irinotecan and cis- platin in advanced non - small cell lung cancer: A muhicenter phase 11 study[ J]. Clin Cancer Res,2001,7 ( 1 ) :68.
  • 8Kenyon BM. Effects of thalidom ide and related metabolites in a mouse comeal of nevoscularization [ J ]. Exp Eye Res, 1997,64:971.
  • 9Or R. Thalidomide reduces vascular density in granulationtissue of subcutaneously implantsd polyvingyl alcohol pongees in guinea pigs [ J ]. Exp Hematol, 1998,26 : 217.
  • 10Nishiwaki Y, Kawahara M. Irinotecan plus cisplatin complatin corn- pared with etoposide pule cisplatin for extehsive small cell lung cancer [J]. N Engl J Med,2002,346(2) :126.

共引文献55

同被引文献56

  • 1Dong, Zhi-Zhen,Yao, Deng-Fu,Wu, Wei,Yao, Min,Yu, Hong-Bo,Shen, Jun-Jun,Qiu, Li-Wei,Yao, Ning-Hua,Sai, Wen-Li,Yang, Jun-Ling.Delayed hepatocarcinogenesis through antiangiogenic intervention in the nuclear factor-kappa B activation pathway in rats[J].Hepatobiliary & Pancreatic Diseases International,2010,9(2):169-174. 被引量:31
  • 2Giltnane JM, Balko JM. Rationale for targeting the Ras/MAPK pathway in triple -negative breast cancer[ J]. Discov Med ,2014, 17(95) :275 -283.
  • 3Presson AP, Yoon NK, Bagryanova L, et al. Protein expression based nmhimarker analysis of breast cancer samples [ J ]. BMC Cancer,2011,110:230.
  • 4Davis AA, Kaklamani VG. Metabolic syndrome and triple negative breast cancer: a new paradigm [ J ]. Int J Breast Cancer,2012:809 - 891.
  • 5Curigliano G, Goldhirsch A. The triple - negative subtype: newideas for the poorest prognosis breast cancer [ J ]. Natl Cancer Inst Monogr,2011,43 : 108 - 110.
  • 6Ece Simsekfiz, Esra Aydemir, Kayahan, et al. DMSO exhibits similar cytotoxieity effects to thalidomide in mouse breast cancer eellose [ J]. Oneol Lett ,2012,3 (4) :927 - 929.
  • 7Gordinier ME, Dizon DS, Weitzen S, et al. Oral thalidomide as pal- liative chemotherapy in women with advanced ovarian cancer[ J ]. J Palliative Med,2007,10( 1 ) :61 -66.
  • 8Howard A Burris, Suzanne F Jones, Dianna Shipley, et al. Phase Ⅱ study of capecitabine incombination with thalidomide inpatients with metastatic breast cancer [ J ]. Cancer Invest, 2010,28 ( 4 ) : 408 -412.
  • 9De Souza CM, Aratjoe Silva AC, de Jesus Ferraciolli C, et al. Combination therapy with carboplatin and thalidomide suppresses tumor growth and metastasis in 4T1 murine breast cancer model [J]. Biomed Pharmacother,2014,68( 1 ) :51 -57.
  • 10Belani CP,Fossella F. Elderly subgroup analysis of arandomized phase Iff study of docetaxel plus platinumcombinations versus vinorelbine plus cisplatin for first-linetreatment of advanced nonsmall cell lung carcinoma (TAX326)[J]. Cancer,2005,104(12):2766-2774.

引证文献6

二级引证文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部